SEC Form 4 · accession 0001933414-26-000100
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon Congleton
Officer — Chief Executive Officer · Director
Period of report
Jul 13, 2026
Accepted (ET)
Jul 15, 2026 · 8:58 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 13, 2026 | S | 10,700 | $27.2375 | D | 603,621 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.58. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.